Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C60H108O8 |
| Molecular Weight | 957.4947 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H](COC(=O)CCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCC\C=C/CCCCCCCC
InChI
InChIKey=PRXRUNOAOLTIEF-ADSICKODSA-N
InChI=1S/C60H108O8/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-56(62)65-53-55(67-57(63)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2)60-59(54(61)52-66-60)68-58(64)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3/h25-30,54-55,59-61H,4-24,31-53H2,1-3H3/b28-25-,29-26-,30-27-/t54-,55+,59+,60+/m0/s1
| Molecular Formula | C60H108O8 |
| Molecular Weight | 957.4947 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 3 |
| Optical Activity | UNSPECIFIED |
Sorbitan Trioleate (Tween 85) is a triester of oleic acid and hexitol anhydrides derived from sorbitol. It functions as a surfactant and emulsifying agent. This product is a white to tan-colored solid. In cosmetics and personal care products, Sorbitan Esters are used in a variety of products including skin care products, skin cleansing products, moisturizers, eye makeup and other makeup.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Study on subacute toxicity of intravenous sorbitan trioleate (STO) in Wistar rats. | 1983 Nov |
|
| Final report on the safety assessment of sorbitan caprylate, sorbitan cocoate, sorbitan diisostearate, sorbitan dioleate, sorbitan distearate, sorbitan isostearate, sorbitan olivate, sorbitan sesquiisostearate, sorbitan sesquistearate, and sorbitan triisostearate. | 2002 |
|
| Microemulsion Using Polyoxyethylene Sorbitan Trioleate and its Usage for Skin Delivery of Resveratrol to Protect Skin against UV-Induced Damage. | 2015 |
|
| Crystallization kinetics of cocoa butter in the presence of sorbitan esters. | 2017 Jan 1 |
Sample Use Guides
Subacute toxicity of sorbitan trioleate (STO) was carried out using Wistar rats. STO was administered intravenously at dose levels of 12.5, 50.0 and 200.0 mg/kg for 35 days. No influence on general symptom, body weight, food and water consumption and urinalysis were observed. In 200.0 mg/kg group, the hematological examination revealed anemia corresponding to the histological findings of the bone marrow. Biochemical analysis displayed the significant increase and/or decrease of enzyme values in 200.0 mg/kg group. The maximal no-effect level of the STO in Wistar rats was considered to be 50.0 mg/kg.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:02 UTC 2023
by
admin
on
Fri Dec 15 15:00:02 UTC 2023
|
| Record UNII |
QE6F49RPJ1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C83486
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
QE6F49RPJ1
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
DTXSID6027892
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
C75657
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
1876
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
70024-41-8
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
ALTERNATIVE | |||
|
9920343
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
26266-58-0
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
SUB10602MIG
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
100000083814
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
247-569-3
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
2599-45-3
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
ALTERNATIVE | |||
|
1363643
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | RxNorm | ||
|
C005693
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY | |||
|
QE6F49RPJ1
Created by
admin on Fri Dec 15 15:00:02 UTC 2023 , Edited by admin on Fri Dec 15 15:00:02 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
